Average Price Target: $4.50
▲ +116.35% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Eloxx Pharmaceuticals in the last 3 months. The average price target is $4.50, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 116.35% upside from the last price of $2.08.
The current consensus among 3 polled investment analysts is to buy stock in Eloxx Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.